- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ulcerative colitis and other listed indications
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1534KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 247KB)
Tofacitinib – November 2020
Tofacitinib (ulcerative colitis): Tablet 5 mg, Tablet 10 mg: Xeljanz®
Last updated
5 March 2021